Zyprexa appeal rejected by Supreme Court
The U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.
Pharmaceutical
Articles
Lilly, partner find no Bydureon effect on heart rhythm
Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
Lilly diabetes pill recommended for EU approval
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
EU approves Lilly’s weekly diabetes drug Bydureon
European Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug said Tuesday.
Analyst: Lilly drug poised for continued growth
Eli Lilly and Co.'s lung cancer treatment Alimta is poised for continued growth based on recently released study data, according to a new Credit Suisse analyst report.
Medco deal loses its luster
New Jersey-based Medco has hired just 430 workers in Whitestown—far short of its commitment of 1,400 by 2012—and its business trends suggest the company is shrinking, not growing.
Lilly enters collaboration deal with Swiss company
Drugmaker Eli Lilly and Co. has signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo and develop other potential orthopedic treatments.
Drug industry outlook negative through 2012, Moody’s says
Earnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
Medco may seek acquisition with biggest contract imperiled
Medco Health Solutions Inc., which operates a $140 million automated pharmacy and distribution center in Whitestown, has lost $3.5 billion in contracts since March.
Lilly licenses Xigris rights to new biotech firm
Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
Prescription drug abuse growing problem in Indiana
Prescription drugs are playing an increasing role in the drug-related crimes that are filling up Indiana's prisons, prison officials and prosecutors said.
Amylin sues Lilly over drug development deal
Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.
Lilly drug to detect Alzheimer’s criticized by consumer group
Eli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain, shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
Two wins to bring Lilly modest sales
Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.
FDA OKs new diabetes pill from Lilly, Boehringer
The Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients who can't control their blood sugar with older medicines.
Lilly teams with Medtronic on Parkinson’s treatment
Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease.
Wellfount nabs $6M in venture capital
The Indianapolis-based institutional pharmacy, which serves long-term-care facilities, wants to expand its business nationally.
Analysts demand news on next Lilly blockbuster
Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.
FDA wants further testing of Lilly pancreas drug
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
Feds: CVS to pay $17.5M over inflated Rx claims
The U.S. Justice Department says CVS Pharmacy Inc. has agreed to pay $17.5 million to settle allegations it overcharged Medicaid programs in 10 states, including Indiana.